Skip to main content

Table 5 Drug-resistant profiles of retreatment patients stratified by age groups

From: Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study

 15–34
(n = 68)
35–59
(n = 275)
≥60
(n = 354)
Total
(n = 697)
p-value
Any drug resistance27 (39.7%)69 (25.1%)78 (22.0%)174 (25.0%)0.009
Resistant to
 INH20 (29.4%)55 (20.0%)65 (18.4%)140 (20.1%)0.114
 RIF22 (32.4%)47 (17.1%)26 (7.3%)95 (13.6%)0.000
 Rfb10 (14.7%)31 (11.3%)13 (3.7%)54 (7.7%)0.000
 EMB7 (10.3%)27 (9.8%)15 (4.2%)49 (7.0%)0.014
 PZA5 (7.4%)21 (7.6%)9 (2.5%)35 (5.0%)0.010
 Km2 (2.9%)9 (3.3%)2 (0.6%)13 (1.9%)0.036
 Am2 (2.9%)6 (2.2%)2 (0.6%)10 (1.4%)0.131
 Cm2 (2.9%)7 (2.5%)2 (0.6%)11 (1.6%)0.090
 Sm5 (7.4%)15 (5.5%)17 (4.8%)37 (5.3%)0.685
 Lfx7 (10.3%)10 (3.6%)12 (3.4%)29 (4.2%)0.028
 Mfx7 (10.3%)8 (2.9%)11 (3.1%)26 (3.7%)0.011
 Ofx7 (10.3%)9 (3.3%)12 (3.4%)28 (4.0%)0.021
 Pto2 (2.9%)8 (2.9%)5 (1.4%)15 (2.2%)0.393
 Cs1 (1.5%)2 (0.7%)1 (0.3%)4 (0.6%)0.450
 PAS2 (2.9%)10 (3.6%)5 (1.4%)17 (2.4%)0.192
INH-monoresistance4 (5.9%)15 (5.5%)40 (11.3%)59 (8.5%)0.024
RIF-monoresistance6 (8.8%)7 (2.5%)1 (0.3%)14 (2.0%)0.000
Multidrug resistance16 (23.5%)40 (14.5%)25 (7.1%)81 (11.6%)0.000
Resistance to any FQsa7 (10.3%)11 (4.0%)12 (3.4%)30 (4.3%)0.035
Resistance to any SLIDsb2 (2.9%)10 (3.6%)2 (0.6%)14 (2.0%)0.021
  1. Abbreviations: INH isoniazid, RIF rifampicin, Rfb rifabutin, EMB ethambutol, PZA pyrazinamide, Km kanamycin, Am amikacin, Cm capreomycin, Sm streptomycin, Lfx levofloxacin, Mfx moxifloxacin, Ofx ofloxacin, Pto prothionamide, Cs cycloserine, PAS para-aminosalicylic acid, FQs fluoroquinolones, SLIDs second-line injectable drugs
  2. aAny fluoroquinolones refer to levofloxacin, moxifloxacin, or ofloxacin
  3. bAny second-line injectable drugs refer to kanamycin, amikacin, or capreomycin